Literature DB >> 19051494

Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066).

M De Lena1, A Guzzon, S Monfardini, G Bonadonna.   

Abstract

This study describes the clinical, roentgenologic, and histopathologic studies of pulmonary toxicity induced by treatment with bleomycin. In 168 patients with evaluable cases who were treated with different dose schedules of bleomycin, the overall incidence of pulmonary toxicity was 39.8%. The mean total dose producing pulmonary damage was about 100-150 mg/m2. In 31 patients (46%), pulmonary changes were detected only after systematic auscultation of the lungs (fine crepitant rales at one or both bases). In 36 patients (54%), roentgenograms showed reticular or reticular micronodular lesions located mostly at the lower lung zones and at the costophrenic angle 1-2 weeks after the crepitations were noted. In seven patients postmortem examination revealed hyperplasia and endoalveolar migration of type II pneumocytes and macrophages, fibrinous edema, hyaline membranes, and newly formed reticular and collagen fibers within the alveolar septa. The radiologic and histopathologic findings were consistent with the diagnosis of interstitial pneumonia. These pulmonary reactions represent a delayed dose-dependent bleomycin effect and are probably due to the preferential distribution of the drug in the lung tissue.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 19051494

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  15 in total

Review 1.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis.

Authors:  E Fasske; K Morgenroth
Journal:  Lung       Date:  1983       Impact factor: 2.584

Review 4.  Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications.

Authors:  D S Klein; P R Wilds
Journal:  Can Anaesth Soc J       Date:  1983-07

5.  Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study.

Authors:  Jason W Denbo; Liang Zhu; DeoKumar Srivastava; Dennis C Stokes; Saumini Srinivasan; Melissa M Hudson; Kirsten K Ness; Leslie L Robison; Michael Neel; Bhaskar Rao; Fariba Navid; Andrew M Davidoff; Daniel M Green
Journal:  J Am Coll Surg       Date:  2014-03-04       Impact factor: 6.113

6.  Phase I trial of tallysomycin S10b, a bleomycin analogue.

Authors:  F P Paolozzi; R C Gaver; N B Newman; B J Poiesz; S DeFino; A Louie; R L Comis
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 7.  Mechanisms of bleomycin-induced lung damage.

Authors:  J Hay; S Shahzeidi; G Laurent
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

8.  The effect of bleomycin on the uptake and incorporation of [14C]choline into phospholipids in hamster lung tissue slices.

Authors:  M A Hollinger; S N Giri
Journal:  Lipids       Date:  1990-12       Impact factor: 1.880

9.  Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.

Authors:  Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery
Journal:  J Carcinog       Date:  2011-09-21

Review 10.  Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.